EPS for Central Garden & Pet Company (CENTA) Expected At $0.08

November 10, 2018 - By Adrian Mccoy

Central Garden & Pet Company (NASDAQ:CENTA) Logo

Analysts expect Central Garden & Pet Company (NASDAQ:CENTA) to report $0.08 EPS on November, 27.They anticipate $0.00 EPS change or 0.00 % from last quarter’s $0.08 EPS. CENTA’s profit would be $4.67M giving it 90.16 P/E if the $0.08 EPS is correct. After having $0.79 EPS previously, Central Garden & Pet Company’s analysts see -89.87 % EPS growth. The stock decreased 1.27% or $0.37 during the last trading session, reaching $28.85. About 147,494 shares traded. Central Garden & Pet Company (NASDAQ:CENTA) has risen 6.98% since November 11, 2017 and is uptrending. It has underperformed by 8.64% the S&P500.

Central Garden & Pet Company (NASDAQ:CENTA) Ratings Coverage

Among 2 analysts covering Central Garden \u0026 Pet (NASDAQ:CENTA), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Central Garden \u0026 Pet had 2 analyst reports since September 10, 2018 according to SRatingsIntel.

Central Garden & Pet Company, together with its subsidiaries, produces and markets products for the pet, and lawn and garden supplies industries in the United States. The company has market cap of $1.69 billion. It operates through two divisions, Pet and Garden. It has a 12.89 P/E ratio. The Pet segment supplies products for dogs and cats comprising edible bones, edible and non-edible chews, rawhide, dog and cat food and treats, toys, pet carriers, grooming supplies, and other accessories; and food, cages and habitats, toys, chews, and related accessories for birds, small animals, and specialty pets.

Another recent and important Central Garden & Pet Company (NASDAQ:CENTA) news was published by Nasdaq.com which published an article titled: “Detailed Research: Economic Perspectives on Cerus, AdvanSix, Spark Therapeutics, Imperva, Central Garden & Pet …” on October 18, 2018.

Central Garden & Pet Company (NASDAQ:CENTA) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.